top of page


"Working with Sabine has been a great experience. She provided us with detailed and accurate preclinical modeling that helped us to make informed decisions regarding our product development. I was impressed with her of professionalism and her commitment to delivering high-quality results."

Pharma client

"I worked with Sabine to predict a human dose and pharmacokinetic profile for one of our biotech company's therapeutic programs. She was very detail oriented and comprehensive in her analyses and modeling in addition to being a pleasure to work with. I would not hesitate to engage with her again."

CEO of biotech company

Journal Publications

Graham, K., Lienau, P., Bader, B., Prechtl, S., Naujoks, J., Lesche, R., Weiske, J., Kuehnlenz, J., Brzezinka, K., Potze, L., Zanconato, F., Nicke, B., Montebaur, A., Bone, W., Golfier, S., Kaulfuss, S., Kopitz, C., Pilari, S., Steuber, H., Hayat, S., Kamburov, A., Steffen, A., Schlicker, A., Buchgraber, P., Braeuer, N., Font, N.A., Heinrich, T., Kuhnke, L., Nowak-Reppel, K., Stresemann, C., Steigemann, P., Walter, A.O., Blotta, S., Ocker, M., Lakner, A., Mumberg, D., Eis, K., Piccolo, S., Lange, M. (2023). Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling. bioRvix, preprint.

Rauh, U., Wei, G., Serrano-Wu, M., Kosmidis, G., Kaulfuss, S., Siegel, F., Thede, K., McFarland, J., Lemke, C., Werbeck, N., Nowak-Reppel, K., Pilari, S., Menz, S., Ocker, M., Kaushik, V., Ziegelbauer, K., Golub, T. (2023). ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Research Square, preprint.

Pilari, S., Gaub, T., Block, M., & Görlitz, L. (2017). Development of physiologically based organ models to evaluate the pharmacokinetics of drugs in the testes and the thyroid gland. CPT: pharmacometrics & systems pharmacology, 6(8), 532-542.

Fronton, L., Pilari, S., & Huisinga, W. (2014). Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. Journal of pharmacokinetics and pharmacodynamics, 41, 87-107.

Huisinga, W., Solms, A., Fronton, L., & Pilari, S. (2012). Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT: pharmacometrics & systems pharmacology, 1(9), 1-10.

Held, M., Imhof, P., Keller, B. G., & Noé, F. (2012). Modulation of a Ligand’s Energy Landscape and Kinetics by the Chemical Environment. The Journal of Physical Chemistry B, 116(46), 13597-13607.

Faelber, K., Held, M., Gao, S., Posor, Y., Haucke, V., Noé, F., & Daumke, O. (2012). Structural insights into dynamin-mediated membrane fission. Structure, 20(10), 1621-1628.

Held, M., & Noé, F. (2012). Calculating kinetics and pathways of protein–ligand association. European journal of cell biology, 91(4), 357-364.

Pilari, S., Preuße, C., & Huisinga, W. (2011). Gestational influences on the pharmacokinetics of gestagenic drugs: a combined in silico, in vitro and in vivo analysis. European journal of pharmaceutical sciences, 42(4), 318-331.

Held, M., Metzner, P., Prinz, J. H., & Noé, F. (2011). Mechanisms of protein-ligand association and its modulation by protein mutations. Biophysical journal, 100(3), 701-710.

Faelber, K., Posor, Y., Gao, S., Held, M., Roske, Y., Schulze, D., Haucke, V., Noé, F., & Daumke, O. (2011). Crystal structure of nucleotide-free dynamin. Nature, 477(7366), 556-560.

Prinz, J. H., Wu, H., Sarich, M., Keller, B., Senne, M., Held, M., Chodera, J.D., Schütte, C., & Noé, F. (2011). Markov models of molecular kinetics: Generation and validation. The Journal of chemical physics, 134(17), 174105.

Prinz, J. H., Held, M., Smith, J. C., & Noé, F. (2011). Efficient computation, sensitivity, and error analysis of committor probabilities for complex dynamical processes. Multiscale Modeling & Simulation, 9(2), 545-567.

Pilari, S., & Huisinga, W. (2010). Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. Journal of pharmacokinetics and pharmacodynamics, 37, 365-405.

bottom of page